Russia's Biocad shifting all biomanufacturing to EU
Biocad says from 2021 all its biologic products will be made in the Europe Union, including its recently approved infliximab biosimilar.
Biocad says from 2021 all its biologic products will be made in the Europe Union, including its recently approved infliximab biosimilar.
Sartorius expects its Bioprocess Solutions Division to make €2.8bn ($3.4bn) annually by 2025 through a mix of organic growth and technology bolt-ons.
ABEC has expanded manufacturing in Ireland with the completion of an ISO-7 cleanroom, where the single-use vendor will make disposable bioreactor bags for global distribution.